.png){kind=icon}
.png){kind=icon}
Return
Real-world comparison of herpes zoster risk among five Janus kinase inhibitors in rheumatoid arthritis: the ANSWER cohort study
.png){kind=icon}
OA
AI
Y
Y
Y
K
T
R
M
I
N
Y
C
Y
H
Y
A
T
W
A
S
K
DOI：10.1016/j.jbspin.2026.106080.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Real-world data enabled comparison of herpes zoster risk among five JAK inhibitors. • Filgotinib showed a lower observed herpes zoster risk than some other JAK inhibitors. • No differences were observed in treatment retention. • Patient factors were not associated with herpes zoster risk after adjustment. • Further large-scale studies are warranted to confirm these findings.
Keywords:
Filgotinib
Herpes zoster
Janus kinase inhibitors
Real world data analysis
Rheumatoid arthritis
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4.3
Papers:
4.2K
Citations:
4.8K
Organization
No organization information available
Cited Papers